Wedbush analyst Michael Pachter upgrades FuboTV (NYSE:FUBO) from Neutral to Outperform.
Harpoon Therapeutics To Present Interim Results From Phase 1 Clinical Trial Of T Cell Engager HPN217 At The 64th ASH Annual Meeting And Exposition
Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present updated interim data from its Phase 1 clinical trial evaluating